Foresee Pharmaceuticals Co Ltd - Asset Resilience Ratio
Foresee Pharmaceuticals Co Ltd (6576) has an Asset Resilience Ratio of 4.79% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Foresee Pharmaceuticals Co Ltd PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2024)
This chart shows how Foresee Pharmaceuticals Co Ltd's Asset Resilience Ratio has changed over time. See Foresee Pharmaceuticals Co Ltd net asset quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Foresee Pharmaceuticals Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Foresee Pharmaceuticals Co Ltd worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$75.00 Million | 4.79% |
| Total Liquid Assets | NT$75.00 Million | 4.79% |
Asset Resilience Insights
- Limited Liquidity: Foresee Pharmaceuticals Co Ltd maintains only 4.79% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Foresee Pharmaceuticals Co Ltd Industry Peers by Asset Resilience Ratio
Compare Foresee Pharmaceuticals Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA |
Drug Manufacturers - Specialty & Generic | 1.28% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026 |
Drug Manufacturers - Specialty & Generic | -0.89% |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Xeris Pharmaceuticals Inc
NASDAQ:XERS |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Procter & Gamble Health Limited
NSE:PGHL |
Drug Manufacturers - Specialty & Generic | 33.01% |
Annual Asset Resilience Ratio for Foresee Pharmaceuticals Co Ltd (2019–2024)
The table below shows the annual Asset Resilience Ratio data for Foresee Pharmaceuticals Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 3.47% | NT$75.00 Million ≈ $2.36 Million |
NT$2.16 Billion ≈ $68.03 Million |
-14.93pp |
| 2023-12-31 | 18.40% | NT$342.50 Million ≈ $10.79 Million |
NT$1.86 Billion ≈ $58.65 Million |
-5.81pp |
| 2021-12-31 | 24.21% | NT$397.46 Million ≈ $12.52 Million |
NT$1.64 Billion ≈ $51.71 Million |
+1.51pp |
| 2020-12-31 | 22.70% | NT$476.68 Million ≈ $15.02 Million |
NT$2.10 Billion ≈ $66.15 Million |
+17.93pp |
| 2019-12-31 | 4.77% | NT$48.16 Million ≈ $1.52 Million |
NT$1.01 Billion ≈ $31.80 Million |
-- |
About Foresee Pharmaceuticals Co Ltd
Foresee Pharmaceuticals Co., Ltd. operates as biopharmaceutical company in the United States, China, and Europe. The company's stabilized injectable formulation pipeline includes FP-001, which completed Phase III clinical study for the treatment of advanced stage prostate cancer; FP-004 that is in preclinical stage to treat opioids use disorder; FP-011 and FP-014, a long-acting sustained release … Read more